Insights › Energy & climate › November 18, 2026
Energy & climate · Pipeline & development

Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation

PR Newswire (Health) Published: Results

First-in-human evidence of exaluren-mediated readthrough of collagen IV in patients with nonsense mutation Alport syndrome Kidney biopsies showed increased collagen IV abundance and partially improved podocyte morphology in all three participants Exaluren was well tolerated, with no...

Original source
Read the source — prnewswire.com ↗

We link to the original publisher. The summary above is a short guide; read the original for the full details.

More in Energy & climate

See everything in Energy & climate →

Look into this further

Read every record in your own language

This page shows the three newest items per field. Members see every record in the field, in 109 languages, with the search engines that work on them.

Read it all — start from $3No app-store installation. Cancel any time.